Physician-administered clinical score of vulvar lichen sclerosus: A study of 36 cases

Naswa, Smriti; Marfatia, Yogesh S

doi:10.4103/0253-7184.167169

Cited by 13 publications

(26 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study covering 36 VLS patients, Naswa et al . pointed out that atrophy, hyperkeratosis and erosion are three of the most frequent lesions in addition to hypopigmentation, which was consistent with the result of the present study.…”

Section: Discussionsupporting

confidence: 93%

“…The reason that the age of onset was found to be so different from most other reports is still unclear, which was speculated to be that most of our patients were urban females who had stronger health‐care awareness and more chance of receiving a timely diagnosis of VLS in high‐level hospitals. Also, several reports indicated that VLS was not common in perimenopausal women …”

Section: Discussionmentioning

confidence: 99%

“…Also, several reports indicated that VLS was not common in perimenopausal women. 6,7 The etiology of VLS is still mostly unknown. Currently, it is mainly considered as an autoimmune disorder which was explained by two antibodies against extracellular matrix protein-1 and BP180, as well as a few other autoimmune disorders detected in some LS patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Vulvar lichen sclerosus: A single‐center retrospective study in China

Yang

Wen

Chang

2018

The Journal of Dermatology

View full text Add to dashboard Cite

Vulvar lichen sclerosus (VLS) is an uncommon, chronic inflammatory skin disease lacking clinical data of large sample size in China. This study was intended to provide missing data on this condition through investigating the clinical characteristics of Chinese VLS patients. The medical records of 129 VLS patients from our vulvar outpatient clinic were analyzed with SPSS version 18.0 software. The age of onset followed a normal distribution, with the peak at 25-30 years. Of all cases, the incidence rate during the postmenopausal period was 14.0% with an average duration of 9.22 years. The most frequently involved site was the bilateral labia minora (71.3%). Itching was the principal symptom (94.6%); meanwhile, patients with severe itching more commonly experienced longer duration, flaring at night, hyperkeratotic lesions or rashes on the posterior commissure than those with mild to moderate itching (P < 0.05). Furthermore, 60% of the enrolled patients suffered from sexual dysfunction. The major sign was pallor (92.2%), followed by hyperkeratosis (55.0%) and atrophy (40.3%). The patients with atrophy had a significantly longer duration of the disease, and the older patients presented more frequently with edema in the area of lesions (both P < 0.05). Of our patients, 9.3% suffered concomitantly from autoimmune diseases, mostly thyroid with one case being complicated by vulvar squamous cell carcinoma (SCC). In our study, the severity of pruritus was partly related to clinical manifestations. Moreover, Chinese patients could have developed VLS mostly in the reproductive period, with less complications of autoimmune diseases or SCC.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vulvar lichen sclerosus: A single‐center retrospective study in China

Yang

Wen

Chang

2018

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Naswa and Marfatia[25] have administered a physician clinical score on the basis of clinical symptoms of erosions, hyperkeratosis, fissures, agglutination, stenosis, and atrophy. They graded them as Grade 1 - no changes or normal, Grade 2 - moderate, and Grade 3 - severe.…”

Section: Differential Diagnosis and Workupmentioning

confidence: 99%

“…According to Naswa and Marfatia, it cannot replace confirmation of VLS by histopathology, so biopsy is still mandatory in doubtful cases. [25]…”

Section: Differential Diagnosis and Workupmentioning

confidence: 99%

Vulvar lichen sclerosus et atrophicus

Nair

2017

J Mid-life Health

View full text Add to dashboard Cite

Vulvar lichen sclerosus (VLS) is a chronic inflammatory dermatosis characterized by ivory-white plaques or patches with glistening surface commonly affecting the vulva and anus. Common symptoms are irritation, soreness, dyspareunia, dysuria, and urinary or fecal incontinence. Anogenital lichen sclerosus (LS) is characterized by porcelain-white atrophic plaques, which may become confluent extending around the vulval and perianal skin in a figure of eight configuration. Thinning and shrinkage of the genital area make coitus, urination, and defecation painful. LS is not uncommon in India and present as an itchy vulvar dermatosis which a gynecologist may mistake for candidal vulvovaginitis. There is often a delay in diagnosis of VLS due to its asymptomatic nature and lack of awareness in patients as well as physicians. Embarrassment of patients due to private nature of the disease and failure to examine the genital skin properly are the other reasons for delay in diagnosis. There is no curative treatment for LS. Various medications available only relieve the symptoms. Chronic nature of the disease affects the quality of life. Proper and regular follow-up is required as there are chances of the development of squamous cell carcinoma.

show abstract

Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial

Viereck

Gamper

Regauer

et al. 2023

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose Vulvar lichen sclerosus (LS) is a chronic debilitating inflammatory skin disease. Today, the gold standard is a life-long topical steroid treatment. Alternative options are highly desired. We present a study protocol of a prospective, randomized, active-controlled, investigator-initiated clinical trial comparing a novel non-invasive dual Nd:YAG/Er:YAG laser therapy with the gold standard for the management of LS. Methods We recruited 66 patients, 44 in the laser arm and 22 in the steroid arm. Patients with a physician-administered clinical LS score ≥ 4 were included. Participants received either four laser treatments 1–2 months apart, or 6 months of topical steroid application. Follow-ups were planned at 6, 12, and 24 months. The primary outcome looks at the efficacy of the laser treatment at the 6-month follow-up. Secondary outcomes look at comparisons between baseline and follow-ups within the laser or the steroid arm, and comparisons between laser vs. steroid arm. Objective (LS score, histopathology, photo documentation) and subjective (Vulvovaginal Symptoms Questionnaire, symptom VAS score, patient satisfaction) measurements, tolerability, and adverse events are evaluated. Conclusion The findings of this trial have the potential to offer a novel treatment option for LS. The standardized Nd:YAG/Er:YAG laser settings and the treatment regime are presented in this paper. Clinical trial identification number NCT03926299.

show abstract

Physician-administered clinical score of vulvar lichen sclerosus: A study of 36 cases

Cited by 13 publications

References 5 publications

Vulvar lichen sclerosus: A single‐center retrospective study in China

Vulvar lichen sclerosus: A single‐center retrospective study in China

Vulvar lichen sclerosus et atrophicus

Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial

Contact Info

Product

Resources

About